




RealRate

PHARMACEUTICAL 2020

Arcus Biosciences Inc
Rank 103 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Arcus Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcus Biosciences Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 96% points. The greatest weakness of Arcus Biosciences Inc is the variable Research and Development, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 319%, being 81% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	192,705
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,706
Liabilities, Non-Current	806
Other Assets	1,075
Other Compr. Net Income	171
Other Expenses	0
Other Liabilities	15,756
Other Net Income	3,999
Other Revenues	15,000
Property and Equipment	9,330
Research and Development	78,481
Selling, General and Administrative Expense	25,228

Output Variable	Value in 1000 USD
Assets	203,110
Liabilities	39,268
Expenses	103,709
Revenues	15,000
Stockholders Equity	163,842
Net Income	-84,710
Comprehensive Net Income	-84,624
BaseVar	182,628
ECR before Limited Liability	225%
Economic Capital Ratio	319%